These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 25567324

  • 1. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
    Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M, EUHASS participants.
    Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
    [Abstract] [Full Text] [Related]

  • 2. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M, EUHASS Participants.
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [Abstract] [Full Text] [Related]

  • 3. Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project.
    Fischer K, Lewandowski D, Marijke van den Berg H, Janssen MP.
    Haemophilia; 2012 May; 18(3):e241-6. PubMed ID: 22044445
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD, Schoenig-Diesing C, Silvati-Fidell L, Wong WY, Romanov V.
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [Abstract] [Full Text] [Related]

  • 6. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L.
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
    Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M, European HAemophilia Safety Surveillance (EUHASS) participants.
    Res Pract Thromb Haemost; 2024 May; 8(4):102461. PubMed ID: 39026659
    [Abstract] [Full Text] [Related]

  • 9. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
    Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U.
    Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.
    Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettle A, Samji N, Rivard GÉ, Carcao M, Iorio A, Makris M, EUHASS and CHESS participants.
    Res Pract Thromb Haemost; 2023 Nov; 7(8):102265. PubMed ID: 38193044
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lalezari S, Misgav M, Martinowitz U, Kenet G.
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [Abstract] [Full Text] [Related]

  • 14. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J, Refacto St Louis Study Group.
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review.
    Franchini M, Tagliaferri A, Mengoli C, Cruciani M.
    Crit Rev Oncol Hematol; 2012 Jan; 81(1):82-93. PubMed ID: 21277222
    [Abstract] [Full Text] [Related]

  • 17. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A, STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS.
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [Abstract] [Full Text] [Related]

  • 18. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I, Mauser-Bunschoten EP, Roosendaal G, Schutgens R, Fischer K.
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [Abstract] [Full Text] [Related]

  • 19. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
    Berntorp E.
    Hamostaseologie; 2017 Jan 31; 37(1):53-57. PubMed ID: 27878207
    [Abstract] [Full Text] [Related]

  • 20. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L, Pollmann H, Becker T.
    Haemophilia; 2012 Jul 31; 18(4):496-502. PubMed ID: 22250808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.